Global Markets Direct’s pharmaceuticals report, “Meda AB - Product Pipeline Review - 2013” provides data on the Meda AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Meda AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Meda AB and industry-specific third party sources, put together by Global Markets Direct’s team.
- Meda AB - Brief Meda AB overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Meda AB human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Meda AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Meda AB’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Meda AB’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Meda AB in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Meda AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Meda AB. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Meda AB and identify potential opportunities in those areas.
Table Of Contents
Meda AB - Product Pipeline Review - 2013 Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Meda AB Snapshot 4 Meda AB Overview 4 Key Information 4 Key Facts 4 Meda AB - Research and Development Overview 5 Key Therapeutic Areas 5 Meda AB - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Meda AB Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Phase I Products/Combination Treatment Modalities 10 Meda AB - Drug Profiles 11 Dexpirronium 11 Product Description 11 Mechanism of Action 11 RandD Progress 11 flupirtine maleate 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 Onsolis 13 Product Description 13 Mechanism of Action 13 sotirimod 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 Meda AB - Pipeline Analysis 15 Meda AB - Pipeline Products by Therapeutic Class 15 Meda AB - Pipeline Products By Target 16 Meda AB - Pipeline Products By Mechanism of Action 17 Meda AB - Recent Pipeline Updates 18 Meda AB - Dormant Projects 20 Meda AB - Company Statement 21 Meda AB - Locations And Subsidiaries 22 Head Office 22 Other Locations and Subsidiaries 22 Appendix 23 Methodology 23 Coverage 23 Secondary Research 23 Primary Research 23 Expert Panel Validation 23 Contact Us 24 Disclaimer 24
List of Tables
Meda AB, Key Information 4 Meda AB, Key Facts 4 Meda AB - Pipeline by Indication, 2013 6 Meda AB - Pipeline by Stage of Development, 2013 7 Meda AB - Monotherapy Products in Pipeline, 2013 8 Meda AB - Phase II, 2013 9 Meda AB - Phase I, 2013 10 Meda AB - Pipeline By Therapeutic Class, 2013 15 Meda AB - Pipeline By Target, 2013 16 Meda AB - Pipeline Products By Mechanism of Action, 2013 17 Meda AB - Recent Pipeline Updates, 2013 18 Meda AB - Dormant Developmental Projects,2013 20 Meda AB, Subsidiaries 22
List of Figures
Meda AB - Pipeline by Indication, 2013 6 Meda AB - Pipeline by Stage of Development, 2013 7 Meda AB - Monotherapy Products in Pipeline, 2013 8 Meda AB - Pipeline By Therapeutic Class, 2013 15 Meda AB - Pipeline Products By Mechanism of Action, 2013 17